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Welcome!
Walking through Washington, D.C., it’s 
easy to be drawn in by the kaleidoscope of unique 
sights and sounds that make up each neighbor-
hood. From the quiet shores of the Potomac in 
the George Washington University’s (GW) Foggy 
Bottom home to the bustle of Capitol Hill, the 
communities we serve are as diverse as the resi-
dents that call D.C., Maryland, and Virginia home. 
But the historic charm of our neighborhoods of-
ten masks the difficult truth – health disparities 
and economic inequality continue to dispropor-
tionately affect some communities, often mani-
festing in a higher cancer burden, less access to 
care, and worse health outcomes.
 At the GW Cancer Center, we believe we have 
a responsibility to work toward health equity. 
Whether at the patient’s bedside or crunching 
data in a lab, connection with the communities we 
serve forms the foundation of everything we do. 
That’s why we chose “re:connect” as the theme of 
this issue — it’s part of our mission to listen, un-
derstand, and address many of the problems that 
are unique to our region so that, ultimately, we 
see progress against cancer at a population level. 
This year we welcomed Carla J. Berg, PhD, 
MBA, as our associate center director for popu-
lation sciences and policy. Berg’s strong back-
ground in multilevel determinants of health 
bolsters our efforts to address prevention and 
strengthens our connections with our colleagues 
in public health and policy. 
In the city that has among the highest percent-
ages of individuals who identify as lesbian, gay, bi-
sexual, transgender, queer, or intersex (LGBTQI), 
the GW Cancer Center is ensuring residents are 
heard through the LGBTQI Research Community 
Advisory Board, which comprises more than a 
dozen representatives from the metro Washing-
ton, D.C., area and local organizations. Connec-
tion also comes by reaching out to our community 
to provide access to critical services and innova-
tive trials. This year, the GW Mammovan, a self-
contained mobile breast imaging clinic, celebrat-
ed nearly 25 years of addressing regional gaps 
in access to mammography services. At the GW 
Cancer Center, patients can also connect with the 
latest clinical trials, like new studies for patients 
with cutaneous squamous cell carcinoma.
Connection can also mean metrics and data. By 
measuring the impact of Medicaid policy changes 
on patient care, we can better communicate with 
policymakers and inform future structural efforts. 
We’re collecting data on a biological level through 
our AIDS and Cancer Specimen Resource, which 
was recently awarded a prestigious five-year grant 
from the National Institutes of Health to connect 
and meet the needs of researchers nationwide 
studying HIV-associated cancers. 
Connection also continues internally by build-
ing bridges between population scientists, clini-
cians, and basic/translational scientists; breaking 
down silos to create a community of excellence 
where all those with the intent to serve others 
and lessen the alarming cancer disparities in the 
greater Washington, D.C., area are welcome.    
As we open a new decade of innovation and 
progress here at the GW Cancer Center, I am ex-
cited to see what the future holds. I hope you’ll 
join me as we share responsibility for, and renew 
our commitment to, health equity in every corner 
of our enterprise and maximize our impact upon 
the community we serve.  
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GW Researcher Investigates  
Role of BRCA1 in DNA Repair
a researCh team leD by Yanfen 
Hu, PhD, professor of anatomy and 
cell biology at the George Wash-
ington University (GW) School of 
Medicine and Health Sciences and a 
member of the GW Cancer Center, 
is studying the role of the tumor sup-
pressor BRCA1 in the homologous 
recombination pathway, the body’s 
mechanism for DNA double-strand 
repair. 
“Our work seeks to validate a pre-
viously unrecognized role of BRCA1 
in licensing the commitment step in 
homologous recombination [a type 
of ‘high-quality’ repair machinery 
that faithfully repairs DNA double-
strand breaks,]” said Hu. “This chal-
lenges the current view of BRCA1 
as merely a scaffolding protein.”
Based on preliminary data, the 
team hypothesizes that BRCA1 
modifications are part of a process 
that senses the damage, but man-
ages to time the fix to that window 
of high-quality repair. Interest-
ingly, both nuclease recruitment 
and inhibition are part of the 
timing control strategy. They also 
propose that the repair activity is 
particularly important for genetic 
integrity of luminal genes in lumi-
nal cells of breast tissue, where 
many BRCA1-associated tumors 
originate.
IN BRIEF
the george Washington university (gW) Summer Program Advancing 
Research on Cancer (GW-SPARC) welcomed its second cohort of under-
graduates from universities across the United States over summer break. The 
program is open to undergraduate students from groups underrepresented 
in the biomedical sciences and provides participants with a hands-on ap-
proach to cancer research. This year, GW-SPARC expanded to include any 
undergraduate students in GW Cancer Center laboratories. 
Through the program, students have the opportunity to work in GW Cancer 
Center labs alongside mentors and gain experience conducting research. At 
the end of the summer, students presented at a poster session open to under-
graduates in labs across GW, including in chemistry and engineering.
“The process of discovery, innovation, and the intellectual freedom that 
you get in [research] when you are passionate about science excites me,” said 
Adriana Hernandez, a participant in the GW-SPARC program from the Uni-
versity of Puerto Rico at Ponce. “Having this experience has made me more 
interested in continuing in cancer research.”
Lighting a SPARC
The GW-SPARC program is open to undergraduate students  
from groups underrepresented in the biomedical sciences. 
HANDS-ON APPROACH
Through the GW-SPARC program, 
students have the opportunity 
to work in GW Cancer Center 
labs alongside mentors and gain 
experience conducting research. 
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kimberly Cabe, FnP-bC, a graDu-
ate student majoring in integrative 
medicine at the George Washington 
University School of Medicine and 
Health Sciences, received the BUCK 
Cancer Foundation 2019 Pay A BUCK 
Forward educational grant  
for $4,000.
A family nurse practitioner, Cabe 
has a dedication to patient-centered 
care that, combined with her con-
tinuing education through multiple 
graduate programs, made her stand 
out from other applicants.  
The Pay A BUCK Forward educa-
tional grant program offers pay-back 
grants to students pursuing a degree 
in integrative medicine or a comple-
mentary cancer treatment. The grant 
provides funds to selected students 
with the expectation that once they 
graduate and are fully employed, they 
will pay back 
the grant as 
a percentage 
of their salary. 
GW Graduate 
Student Receives 
Grant from BUCK 
Cancer Foundation
aCComPlisheD meDiCal onCologist george kim, MD, recently 
joined the GW Cancer Center as director of its Gastrointestinal Can-
cers Program.
The program brings together medical, surgical and radiation 
oncologists, interventional radiologists, gastroenterologists, genetic 
counselors, nutritionists, and other supportive care professionals. The 
multidisciplinary model provides patients with access to multiple spe-
cialties working together as a team and improves outcomes  
for patients.
Kim, who specializes in colorectal, pancreatic, liver, and gastric 
esophageal cancers, most recently provided medical oncology ser-
vices at 21st Century Oncology in Florida. He previously worked at the 
Mayo Clinic in Jacksonville, Florida, and the National Cancer Institute in 
Bethesda, Maryland.
Kim also has an extensive research background, including serving 
as the principal investigator for clinical trials studying the effectiveness 
of different treatments for gastrointestinal cancers. 
George Kim, MD, New Multidisciplinary 
Gastrointestinal Cancers Program Lead
IN BRIEF
NEW PROGRAM 
DIRECTOR 
George Kim, MD, (left) 
recently joined the GW 
Cancer Center as direc-
tor of its Gastrointesti-
nal Cancers Program.
PAYING IT FORWARD
Kimberly Cabe, FNP-BC, 
(left), received the BUCK 
Cancer Foundation 2019 
Pay A BUCK Forward 
educational grant.
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IN BRIEF
unDer the leaDershiP oF vishal 
A. Patel, MD, director of the Cutane-
ous Oncology Program at the George 
Washington University (GW) Cancer 
Center, the center was selected as 
the first global site of a clinical trial 
for patients with high-risk cutaneous 
squamous cell carcinoma. 
The study, sponsored by biotech-
nology company Regeneron in col-
laboration with multinational phar-
maceutical firm Sanofi, will compare 
disease-free survival of patients treat-
ed with adjuvant cemiplimab with 
disease-free survival of those treated 
with placebo after surgery and radia-
tion therapy.
“This selection highlights the com-
mitment of the GW Cancer Center 
to invest in the development of a 
premier multidisciplinary cutaneous 
oncology program in the District of 
Columbia,” said Patel, who leads the 
study. The randomized, placebo-
controlled, double-blind Phase III 
trial is intended to investigate ce-
miplimab’s safety and effectiveness 
in preventing recurrence and me-
tastasis in high-risk cutaneous squa-
mous cell carcinoma. The study is 
estimated to enroll more than 400 
participants worldwide.
GW Cancer Center First Site for Clinical Trial in 
Patients with Cutaneous Squamous Cell Carcinoma
Cemiplimab was approved by the 
U.S. Food and Drug Administration in 
September 2018 to treat patients with 
metastatic cutaneous squamous cell 
carcinoma or locally advanced cuta-
neous squamous cell carcinoma who 
are not candidates for curative surgery 
or curative radiation. The immuno-
therapy treatment was the first treat-
ment approved and available in the 
United States for this type of advanced 
skin cancer.
“By conducting this trial, we hope to 
understand whether this approach can 
help the patient’s own immune sys-
tem control the skin cancer and keep 
it from coming back,” said Mitchell 
Smith, MD, PhD, associate center direc-
tor for clinical investigations at the GW 
Cancer Center.   n 
GLOBAL SITE OF 
CARCINOMA CLINICAL TRIALS
The Cutaneous Oncology Program at 
the GW Cancer Center has been se-
lected as the first global site of a clin-
ical trial for patients with high-risk 
cutaneous squamous cell carcinoma. 
A clinical trial for patients 
with high-risk cutaneous 
squamous cell carcinoma 
lead by Vishal A. Patel, 
MD, is estimated to 
enroll more than 400 
participants worldwide.
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Carla berg, PhD, mba, brings  years 
of expertise to the George Washing-
ton University (GW) Cancer Center in 
the role of associate center director 
for population sciences and policy 
and as a professor of prevention 
and community health at the Milken 
Institute School of Public Health 
at GW.
Berg is a clinical psychologist with 
research expertise in multilevel de-
terminants of health, with an empha-
sis on high-risk populations such as 
young adults, racial minorities, and 
the LGBTQI population. She is a rec-
ognized expert on the implementa-
tion of tobacco control policies and 
health disparities, and has published 
nearly 200 peer-reviewed scientific 
reports and papers.
Carla Berg, PhD, MBA, Joins GW Cancer 
Center to lead Population Sciences and Policy 
IN BRIEF
Berg most recently served as an 
associate professor in the Depart-
ment of Behavioral Sciences and 
Health Education at the Rollins School 
of Public Health at Emory University 
and the associate director for popu-
lation sciences at Emory University’s 
Winship Cancer Institute.
Berg has contributed significantly 
to research focused on reducing 
the global toll of tobacco, the use of 
which is among the world’s leading 
preventable causes of death, killing 
more than 7 million people world-
wide every year. 
“Cancer prevention through 
population-level approaches is a 
critical pillar of our work here at 
the GW Cancer Center,” said Edu-
ardo M. Sotomayor, MD, Dr. Cyrus 
Katzen Family Director of the GW 
Cancer Center and professor 
of medicine at the GW School of Med-
icine and Health Sciences. “Dr. Berg’s 
impressive experience and track 
record of community-engaged re-
search make her a valuable addition 
to our team as we continue to invest 
in cancer prevention and strengthen 
our partnerships in public health.”
Berg earned her PhD in clinical 
health psychology from the Universi-
ty of Kansas. She completed residen-
cy training at Massachusetts General 
Hospital/Harvard Medical School in 
behavioral medicine and completed 
postdoctoral training at the Univer-
sity of Minnesota. She received her 
MBA from the Goizueta Business 
School at Emory University.
“I look forward to working along-
side my colleagues at GW to truly 
make a difference in cancer preven-
tion and control, and in public health 
more broadly, globally, and in our im-
mediate community,” Berg said.   n 
NEW ASSOCIATE DIRECTOR
Carla Berg, PhD, MBA, is the GW 
Cancer Center’s new associate 
center director for popula-
tion sciences and policy.
“Dr. Berg’s impressive 
experience and track 
record of community-
engaged research 
make her a valuable 
addition to our team.”
EDUARDO M. SOTOMAYOR, MD
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Eduardo M. Sotomayor, MD, 
Installed as Inaugural Dr. Cyrus 
Katzen Family Director
With his Formal installation as the inau-
gural Dr. Cyrus Katzen Family Director of the 
George Washington University (GW) Cancer 
Center on Aug. 13, Eduardo M. Sotomayor, MD, 
joined an elite group of 29 endowed professors, 
chairs, and directors throughout the GW School 
of Medicine and Health Sciences (SMHS).
“I am truly honored and humbled to serve as 
the inaugural Dr. Cyrus Katzen Family Director of 
the George Washington University Cancer Cen-
ter,” Sotomayor said. The recognition, he added, 
“is an acknowledgment of the many people who 
influenced and guided me along an exciting jour-
ney that took a boy from a small town along the 
coast of Peru to America, the greatest country, 
which adopted me and allowed me to fulfill my 
personal and professional dreams.”
Sotomayor, a research leader in the study of 
immunotherapy of B-cell malignancies, came to 
GW just four years ago to serve as the director 
of the GW Cancer Center. In those four years, 
Sotomayor has unified GW’s cancer research 
and clinical care, advancing research innovation, 
personalizing cancer care, and supporting can-
cer policy development. His overarching goal for 
the GW Cancer Center is to earn designation as 
a National Cancer Institute (NCI) comprehensive 
cancer center. 
“We know we got the right person for the job,” 
said Jeffrey S. Akman, MD ’81, RESD ’85, former 
vice president for health affairs, Walter A. Bloe-
dorn Professor of Administrative Medicine, and 
dean of SMHS. “We were looking for someone 
with big ideas who could build a cancer center.” 
The search committee, he said, was particularly 
impressed with Sotomayor’s “vision, passion, 
deep knowledge of NCI cancer centers, and de-
sire to build something from the ground up.”
The installation ceremony featured a caval-
cade of honored guests, including members of 
the Katzen and Sotomayor families, the Cyrus 
Katzen Foundation board, current and former 
GW presidents, and senior leadership represent-
ing the university’s health enterprise. Robert C. 
Gallo, MD, a longtime mentor of Sotomayor who 
is best known for his role in the discovery of HIV 
and the development of the HIV blood test, was 
also on hand for the event. 
“Today is a significant day for my entire family,” 
said Jay Katzen, MD ’72, BA ’67. The two-time GW 
“I am truly honored and humbled to serve as the 
inaugural Dr. Cyrus Katzen Family Director of the 
George Washington University Cancer Center.”
EDUARDO M. SOTOMAYOR, MD
NEW DIRECTOR
Eduardo M. Sotomayor, 
MD, (left) is the inau-
gural Dr. Cyrus Katzen 
Family Director.
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alumnus and director of the Cyrus Katzen Foun-
dation recalled his family’s extensive ties to GW 
and the impact cancer has had on his family. 
“We’re here to continue to build upon the 
important legacy my father, Dr. Cy Katzen, has 
established here at GW and in the Washington, 
D.C., region in the area of cancer research and 
patient-related cancer care,” said Katzen, who is a 
member of the SMHS Dean’s Council, a member 
of the Katzen Cancer Research Center Board of 
Directors, and a former member of GW’s Board 
of Trustees, serving from 2010 to 2018. 
The Katzen family’s support over the past 
two decades has been critical to cancer care at 
GW and in Washington, D.C. In 2008, Cyrus and 
Myrtle Katzen made a $10 million gift to estab-
lish the Dr. Cyrus and Myrtle Katzen Cancer 
Research Center.
“Dad made this gift because he knew that 
funding research is the only way to find a cure,” 
recalled Katzen. “He saw potential in GW, and he 
knew that under the right leadership GW could 
have a premier cancer center someday.”
Since then, the Katzen Center has served as 
the medical home for thousands of people in 
their most vulnerable times as they go through 
treatment. 
“Endowed gifts such as this are the corner-
stone of philanthropy,” said GW President Thom-
as LeBlanc. “The earnings they generate enrich 
and sustain our work across the university, reach-
ing all corners of the campus, in perpetuity.”
The gift of an endowed directorship will sup-
port the GW Cancer Center by enhancing basic 
science and translational research and funding 
new treatment protocols, academic needs for 
medical students and clinicians, honoraria for vis-
iting scholars, pilot research grants for residents 
and fellows, and equipment needs. 
Cyrus Katzen’s legacy, Sotomayor added, “is 
one of compassion for patients and their families 
during the life-altering aftermath of cancer diag-
nosis. He and his family lived through this jour-
ney, and they are empathetic partners who share 
our commitment to creating a cancer-free world. 
“Each one of us in this room plays an impor-
tant role in the fight against this terrible disease. 
I look forward to the journey ahead together 
as we continue to fulfill the proud legacy of the 
Katzen family.”   n
a reCent visit to the George Washington 
University (GW), and the school’s 500,000 
square-foot Science and Engineering Hall, left 
Sebastian (then 8) and Luca (then 6) Stafford 
impressed by the volume of research happening 
at the university. The brothers were particularly 
impressed by the high-resolution cancer 
microscopy images decorating the GW Cancer 
Center’s 8th floor lobby. Inspired, the two set up 
a lemonade fundraiser to help support the GW 
Cancer Center. 
Lemon Aid
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MAJOR NIH GRANT SUSTAINS THE LARGEST  
HIV MALIGNANCY SPECIMEN BANK
BIO BANKING
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hiv/aiDs Currently aFFeCts more than 35 
million people worldwide. Infection with HIV is 
associated with a wide range of long-term health 
complications, including the development of 
cancer, which is a major cause of death among 
individuals living with HIV. The AIDS and Cancer 
Specimen Resource (ACSR), the largest collection 
of annotated HIV malignancy specimens globally 
available to researchers, has received renewed 
grant funding, with the George Washington Uni-
versity (GW) serving as the primary site for the 
next five years. The renewal includes a $22 million 
grant from the National Institutes of Health. 
The ACSR was established in 1994 through a 
cooperative agreement with the National Cancer 
Institute (NCI) and is overseen by principal inves-
tigators from the two legacy sites, GW and the 
University of California, San Francisco. The ACSR 
also includes consortia at Baylor Medical College; 
Mayo Clinic in Scottsdale, Arizona; and Stellen-
bosch University in Cape Town, South Africa.
“Through this grant, we are working to acquire, 
store, and equitably distribute tumor tissues and 
biological fluids from individuals with HIV-asso-
ciated malignancies to meet the biospecimen 
needs of researchers studying HIV-associated 
malignancies,” said Sylvia Silver, DA, director of 
the GW Biorepository and professor of microbi-
ology, immunology, and tropical medicine at the 
GW School of Medicine and Health Sciences.
As part of the award, Silver, one of the princi-
pal investigators on the project, will serve as the 
director of the AIDS Malignancy Clinical Trials 
Consortium (AMC) Biorepositories. The AMC, 
which is funded by the NCI, engages more than 
250 clinicians and conducts clinical trials in the 
United States, sub-Saharan Africa, and Latin 
America. Currently, the AMC biorepositories are 
located at GW for U.S. domestic trials and at Stel-
lenbosch University for African trials.
During the grant cycle, Silver will assist NCI in 
the selection of a new ACSR site in Latin America 
to support AMC clinical trials in the region. In 
early 2014, Silver worked closely with her South 
African counterparts to provide quality manage-
ment expertise and advice on best practices as 
Stellenbosch University prepared to launch the 
sub-Saharan African biorepository.
The GW Biorepository has served as a com-
prehensive, state-of-the-art resource for biospec-
imen processing, storage, and disbursement, 
designed to help today’s leading investigators 
facilitate their research. In 2019, the GW Biore-
pository earned designation as a core facility and 
accreditation by the College of American Pathol-
ogists.
The GW Biorepository is one of seven core fa-
cilities — along with the Biostatistics Center, Flow 
Cytometry Core Facility, GW Biomarker Discov-
ery and Analysis Core Facility, McCormick Ge-
nomic and Proteomic Center, Nanofabrication 
and Imaging Center, and the Research Pathology 
Core Labs. These facilities offer a range of ser-
vices, including cutting-edge technologies and 
high-end instrumentation coupled with research 
technical support for university investigators.    n
BY ASHLEY RIZZARDO
BIOREPOSITORY FOR 
DOMESTIC TRIALS
The AIDS and Cancer Specimen 
Resource, the largest collection 
of annotated HIV malignancy 
specimens globally available 
to researchers, has received 
renewed grant funding, with the 
George Washington University 
serving as the primary site for 
the next five years. Sylvia Silver, 
DA, will serve as the director of 
the AIDS Malignancy Clinical Tri-
als Consortium Biorepositories. 
10    re:connect winter 2020
MORE INFORMATION
To learn more about the GW Mammovan  
and to support its mission of curable, 
treatable breast cancer for all women,  
visit www.supportthemammovan.org.
MAMMOVAN
in the Making
in 1995, the Prevent CanCer FounDation, a Washington, D.C., nonprofit, 
conducted a needs assessment of the community and determined that 
the District had many gaps in access to mammography services.
The foundation chose the George Washington University (GW) 
to help close those gaps with its mobile mammography program. 
From that original partnership, as well as with new relationships 
including the Eagle Bank Foundation, GW’s Mammovan has been 
providing mammography services throughout the metropolitan 
area for nearly 25 years. That support has increased access to 
mammography services for nearly 2,000 women annually.
BY THE NUMBERS
Length: 39 feet 
Weight: 14 tons38 women screened in 2018
708 women screened in 2019, as of August 
397 of those screened were uninsured Latinas
Almost 40,000 women screened since Mammovan’s inception
70 partnerships with local organizations
Mammovan can screen 25 patients a day
GOAL
To make lifesaving 
early detection of breast 
cancer possible for all women 
throughout metropolitan 
Washington, regardless of 
their ability to pay
The George Washington University Cancer Center     11
INSIDE THE VAN
 > The GW Mammovan is a self-
contained, customized mobile 
breast imaging clinic bringing 
digital technology with 3D mam-
mograms conveniently to lo-
cal women within minutes. 
 > It is both handicapped- and 
wheelchair-accessible. 
 > It has the most comprehensive 
mammography system available 
today — Genius 3D mammography 
technology with the Hologic Selenia 
Dimensions Mammography System. 
 > The van is spacious, warm, and 
inviting, featuring three climate 
zones and individual chang-
ing rooms with private waiting 
areas for maximum comfort. 
ANNUAL EVENT SUPPORTS  
GW CANCER CENTER’S  
COMMITMENT TO EARLY DETECTION
the george Washington uni-
versity (gW) Cancer Center rolled 
out the pink carpet for the 8th An-
nual GW Blush Luncheon at the 
Ritz-Carlton in Washington, D.C., 
to benefit the GW Mammovan. 
Robert Kelly, MD, former CEO 
of the GW Medical Faculty Associ-
ates, and Jeffrey S. Akman, MD ’81, 
RESD ’85, former vice president for 
health affairs, Walter A. Bloedorn 
Professor of Administrative Medi-
cine, and dean of the GW School 
of Medicine and Health Sciences, 
welcomed the 200-plus attendees 
on hand for the event. Kelly lauded 
the role the Mammovan plays in the 
community, providing access to 
critical mammography services, en-
couraging early detection of breast 
cancer by screening women where 
they live and work, and scheduling 
follow-up services for those who re-
ceive suspicious findings. 
“We celebrate the survivors in 
the room,” Akman told the attend-
ees. “It is our honor to have you 
here with us today. We are commit-
ted to supporting you as you con-
tinue on your journey to wellness.
“This occasion also allows us to 
shine a light on the innovative and 
novel research that is taking place in 
the labs and in the clinics. At GW, our 
researchers are directly responding 
to the needs of our community.”
The annual luncheon highlight-
ed survivor stories as well as an on-
site text-to-donate campaign and a 
silent auction. NBC4 anchorwom-
an Eun Yang again presided over 
the event and offered a special 
tribute in honor of journalist Cokie 
Roberts, a longtime supporter of 
the Blush Luncheon, who died in 
September 2019 following her 17-
year battle with breast cancer. 
The 2019 Community Service 
award was presented to breast can-
cer survivor Marie Sylla-Dixon, vice 
president of T-Mobile, for her long-
standing support for the Mammo-
van. D.C. City Councilmember Vin-
cent Gray presented proclamations 
from the Mayor’s Office and the City 
Council in honor of the occasion.
Nicole Quiroga, CEO of the Great-
er Washington Hispanic Chamber of 
Commerce, served as the featured 
speaker at the luncheon in conver-
sation with Washington Business 
Journal Vice President James Mac-
Gregor. Quiroga drew attention to 
the plight of Hispanic women, who 
typically are diagnosed in the later 
stages of the disease often due to 
a lack of access. She urged women 
to take advantage of all of the re-
sources at their disposal, such as the 
Mammovan, that screen regardless 
of insurance status. 
The event — which featured ma-
jor sponsors including McKesson 
Corporation, GW Hospital, GW 
Medical Faculty Associates, and 
T-Mobile, as well as continued sup-
port from the Safeway Foundation 
and nearly 30 additional sponsors 
and in-kind supporters — raised 
more than $200,000 for 2019. All 
of the proceeds go directly to sup-
port the operational expenses of 
the Mammovan.
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umans, by nature, are complex; they’re sometimes puzzles to be studied and solved. On 
paper, they can be divided and classified, neatly sifted into categories based on codes 
and diagnoses and demographics; this makes them more decipherable, but no less fasci-
nating. For Lorens Helmchen, PhD, a scholar who speaks enthusiastically of his research, 
that deep dive into data and the resulting percentages and probabilities provide insight 
into three parties in health care: patient, provider, and insurer. 
Helmchen’s study, “The Impact of Greater Reimbursement for Chemotherapy Drugs 
on Cancer Care Among DC Medicaid Enrollees,” focuses primarily on the effect of a 2016 
Medicaid policy that increased the reimbursement of physician-administered chemo-
therapy drugs to 100% from 80% of the Medicare fee schedule. The initial funding for 
the study came from the Cyrus and Myrtle Katzen Cancer Research Center’s Catchment 
Area Pilot Awards, which are intended to promote research that improve cancer health 
outcomes for individuals in the Washington, D.C., area.
“What we wanted to do was understand how did care change in the aftermath of this 
policy change,” explains Helmchen, associate professor of health policy and manage-
ment at the Milken Institute School of Public Health at the George Washington University 
(GW) and a member of the GW Cancer Center. 
The preliminary takeaways of this study on the reimbursement change are intriguing: 
providers may increase the frequency of diagnostic testing and aggressive treatment, 
patients may see more health care providers, and financial incentives from insurers can 
be powerful motivators. 
Helmchen cautions that he cannot attribute these changes unambiguously to the 
policy change because the study was descriptive; he looked solely at medical claims of 
patients who were covered by Medicaid and thus were all exposed to the policy change. 
The claims contained patient demographic information — age, gender, race, and place of 
residence — as well as diagnostic and procedural codes. He studied approximately 2,100 
Medicaid enrollees whose medical claims recorded a diagnosis of prostate cancer and 
DELVING INTO DATA 
BY CAROLINE TRENT-GURBUZ
GW CANCER CENTER RESEARCHER EXPLORES  
THE IMPACT OF HEALTH POLICY ON PATIENT CARE
H
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approximately 2,600 Medicaid enrollees whose 
medical claims included a breast cancer diagno-
sis between 2013 and 2017. “We [then] used the 
claims to characterize what happened after the 
policy had gone into effect,” he says. “So, what 
did we find?”
One of the “most salient findings,” he says, was 
on the treatment arc for prostate cancer patients 
diagnosed within the aforementioned five-year 
range. “We detected an increase in the prob-
ability that they would receive a CT scan or an 
MRI scan or a bone scan of about 7.5 percentage 
points, so that’s fairly significant.” 
He also focused on whether these patients re-
ceived any of three types of treatments: chemo-
therapy, radiation, or surgery. “After the policy 
had been implemented in 2016, prostate cancer 
patients in the Medicaid program were about a 
third more likely to receive treatment than be-
fore,” he says.
There was, however, one unexpected finding. 
Helmchen expected patients to receive chemo-
therapy more often than before the policy change 
because its reimbursement had increased. Early 
results indicate otherwise; there was no statisti-
cally significant increase in the use of chemo-
therapy, or radiation and surgery. (Breast cancer 
patients, as a whole, did not see a statistically sig-
nificant change in treatment patterns at all.) 
He notes that the lack of such a change in 
treatment patterns “gives a lot of credit to the 
providers. Financial inducements failed to bring 
about a detectable change in the treatment pat-
terns [for breast and prostate cancer patients], 
other than raising the probability of CT and MRI 
scans for prostate cancer patients and raising the 
overall treatment for prostate cancer patients.”
So, what does that mean? The policy change 
could have appealed to providers to continue 
treating prostate and breast cancers with the 
same number of chemotherapy agents, rather 
than expanding the treatment plan to include 
potentially more chemotherapy or the additional 
invasive options of surgery plus radiation. 
“If [treating patients with chemotherapy 
agents] is financially attractive for providers, then 
providers have an incentive to encourage greater 
rates of diagnosis, so that would be consistent 
with our finding that the probability of receiving 
a CT or MRI scan increased,” Helmchen explains. 
“And … you’re bound to find more cancers if you 
increase the diagnostic effort.”
“If you make it more attractive to provide 
chemotherapy treatment, you make it more at-
tractive for additional providers to see patients, 
so perhaps it’s not too surprising that patients 
would see more providers because they have 
more choice now,” Helmchen concludes.   n
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After a 2016 Medicaid policy increased the 
reimbursement of physician-administered 
chemotherapy drugs, prostate cancer patients 
in the Medicaid program were about a third 
more likely to receive treatment than before.
“Perhaps it’s not too surprising that 
patients would see more providers 
because they have more choice now.”
LORENS HELMCHEN, PhD
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When rong li, PhD, arriveD at the George 
Washington University (GW) School of Medicine 
and Health Sciences (SMHS) in 2018 from the 
University of Texas Health Science Center at San 
Antonio, he was enthusiastic at the prospect of 
becoming a member of the GW Cancer Center. 
“There are several things that excited me 
about GW and the GW Cancer Center,” says Li, 
the Ross Professor of Basic Science Research 
and chair of the Department of Biochemistry and 
Molecular Medicine at SMHS. “There are a lot of 
exciting new initiatives here … In my experience 
here so far, I see a lot of potential for cross-disci-
plinary actions.”
Prior to joining GW, Li — a molecular biologist 
focused on the fundamental aspects of cancer 
biology, particularly how cells duplicate and how 
they acquire mutations — served as a co-leader 
for the Cancer Development and Progression 
Program at the Mays Cancer Center, a National 
Cancer Institute-designated cancer therapy and 
research center. 
Li also leads ongoing research into the tumor 
suppressor gene BRCA1, a gene connected to risk 
for certain cancers, including breast and ovarian 
cancers. His team is par-
ticularly interested in 
the tissue specificity and 
why women who carry 
BRCA1 mutations have a 
particularly high risk for 
developing breast and 
ovarian cancer.
While at the Mays 
Cancer Center, Li saw 
the opportunity to in-
teract with clinician-
scientists and began 
connecting with breast 
oncologists and surgi-
cal oncologists to build 
a cross-disciplinary breast cancer research team.
Li hoped to compare the breast tissue of BR-
CA1-mutation-carrying women with tissue from 
non-carriers to possibly identify an early signa-
ture indicating what is unique about breast tis-
sue and what really happens at the early stage 
of breast cancer development in women who 
carry the mutation. To do that, Li and his cross-
disciplinary team of oncologists and plastic 
surgeons built a collection of patient samples. 
From there, the team worked with genomic ana-
lysts to find signatures that occur only in BRCA1 
mutation carriers.
“In my career, I’ve found that discoveries in sci-
ence often lead you to unexpected territory,” says 
Li, who recently began a project on tumor immu-
nology in his GW Cancer Center lab. It’s an area 
he says he still finds fairly daunting. However, in 
such areas he finds the opportunity to connect 
with clinician-scientists and researchers in other 
basic science departments, such as bioengineer-
ing and microbiology, immunology, and tropical 
medicine, to brainstorm the direction of research.
“Our research benefits tremendously from this 
kind of cross-disciplinary network,” Li says.   n
BUILDING A CROSS-
DISCIPLINARY NETWORK
Rong Li, PhD, joined 
the George Washington 
University (GW) School of 
Medicine and Health Sci-
ences in 2018. He recently 
began a project on tumor 
immunology in his GW 
Cancer Center lab, which 
has provided him with the 
opportunity to connect 
with clinician-scientists 
and researchers in other 
basic science departments. 
Cross-Disciplinary 
Cancer Research
“In my career, I’ve found that 
discoveries in science often lead 
you to unexpected territory.”
RONG LI, PhD
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T QBG
t the George Washington University (GW) Cancer Center, listening to the needs of 
the community is a vital responsibility. That’s why in the city that has among the high-
est percentages of individuals who identify as lesbian, gay, bisexual, transgender, 
queer, or intersex (LGBTQI), the GW Cancer Center is ensuring its residents are al-
ways heard. 
“It’s important that the people you are trying to serve are guiding your priorities. 
Otherwise you’re not doing your job; you’re not meeting their needs,” says Mandi L. 
Pratt-Chapman, PhD, associate center director for patient-centered initiatives and 
health equity at the GW Cancer Center.
One of the ways the center is filling seats at the table is through the LGBTQI Re-
search Community Advisory Board, or CAB, which comprises more than a dozen rep-
resentatives from the metro Washington, D.C., community and local organizations. 
Rachelle Tepel, PhD, community member and former chair of the board, says its 
mission is “to connect health care researchers, specifically in the cancer fields, to 
the LGBTQI community in the D.C. metro area.” The board helps forge important 
connections between researchers and the community. 
In July 2018, the GW Cancer Center, in partnership with health care workers, 
community members, researchers, and D.C. organizations, set the stage for the 
CAB’s work. The center hosted a one-day workshop to facilitate conversations on 
the health needs of the LGBTQI community. From the event emerged top research 
priorities, such as finding solutions for social isolation among transgender women 
and LGBTQI elders, and increasing provision of culturally responsive care for pa-
tients, among others.
Tepel, a member of the LGBTQI community and a cancer survivor, notes that 
in addition to identifying research priorities, education of providers on how to be 
more inclusive is important to the CAB and to her personally.
How to Spell Quality Care Using 
BY KATHERINE DVORAK
LISTENING TO 
THE COMMUNITY
Washington, D.C., has 
among the highest per-
centage of individuals 
who identify as lesbian, 
gay, bisexual, transgen-
der, queer, or intersex. 
The staff at the George 
Washington University 
Cancer Center ensures 
the city’s residents 
are always heard.
WORKING WITH A DIVERSE COMMUNITY IS HELPING THE GW CANCER 
CENTER DEVELOP RESEARCH INNOVATIONS AND CLINICAL CARE FOR ALL
A
L I
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“Because of my experience with health care 
providers in the past, it’s important to me to try to 
get the health care providers to be more aware of 
the needs of the community,” she says.
A year later, the CAB participated in a network-
ing event during which researchers at GW and 
other universities in the area presented the proj-
ects they were working on to community mem-
bers. “Sometimes it feels like we’re asking com-
munity members what they need over and over 
again, but not showing them evidence of what 
we’re doing to try to answer some of those needs. 
We wanted to shift that,” says Pratt-Chapman.
Embracing Lived Experiences
Eduardo M. Sotomayor, MD, Dr. Cyrus Katzen 
Family Director of the GW Cancer Center and 
professor of medicine at the GW School of Medi-
cine and Health Sciences (SMHS), adds that a city 
that ranks high in overall cancer mortality must 
provide equitable care for all. “We want everyone 
who walks in the door to feel empowered, [be] 
engaged, and have ownership over their care,” 
Sotomayor says. 
Relationship and trust building in the LGBTQI 
community is paramount, and something on 
which the GW Cancer Center is focused. 
“There are huge differences among the L, the 
G, the B, the T, the Q, and the I,” Pratt-Chapman 
says. Even within the community, she adds, it’s a 
constant process of learning, building trust, and 
making sure CAB members are focusing on the 
right things. “We need to think about how sex 
and gender identity 
and transgender lived 
experiences affect 
health and how inter-
ventions work.” 
P r a t t - C h a p m a n 
says that technical as-
sistance and training 
provided by her team 
emphasize that each 
person has a unique lived experience. She envi-
sions the creation of sexual and gender minority 
training for cancer centers across the United States, 
with the GW Cancer Center at the forefront of the 
movement. 
Open Trials
Clinical trials are key to research, and making tri-
als open to members of the LGBTQI community 
and ensuring they feel comfortable participating 
is top of mind in the GW Cancer Center Clinical 
Trials Office.
“We want to make all patients feel comfort-
able, feel free to talk with us about any concerns, 
and be open to receive them and give them 
equal opportunity in clinical trials,” says Monica 
Rengifo-Pardo, MD, a clinical research coordina-
tor at the GW Cancer Center. 
Richard Lush, PhD, director of the Clinical Tri-
als Office, adds that there’s no specific outreach 
to the LGBTQI community for trials right now, but 
adds that he wants to make sure that the patients 
enrolled in trials are diverse. 
SEXUAL AND GENDER 
MINORITY TRAINING
Mandi L. Pratt-Chapman, 
PhD, envisions the creation of 
sexual and gender minority 
training for cancer centers 
across the United States, with 
the GW Cancer Center at the 
forefront of the movement.
“It’s important that the people 
you are trying to serve are 
guiding your priorities. Otherwise 
you’re not doing your job; you’re 
not meeting their needs.”
MANDI L. PRATT-CHAPMAN, PhD
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Currently in the works is the development of a 
software system to manage the clinical trials pro-
cess, Lush explains. “We want to ensure that we 
are capturing data about the LGBTQI community 
and how good we are at enrolling them in clinical 
trials. We want to see those data,” he says.
Building Bridges 
The GW Cancer Center is not an island, and 
it relies on support from SMHS, Milken Insti-
tute School of Public Health at GW (Milken In-
stitute SPH), the GW Medical Faculty Associ-
ates, and GW Hospital to further its community 
outreach goals.
“The solutions to most health issues are in the 
space where our different disciplines meet,” says 
Carlos Rodriguez-Diaz, PhD, MPH, associate pro-
fessor in the Department of Prevention and Com-
munity Health at Milken Institute SPH. “We have 
to work from the simplest point, the cell, all the 
way to the policies that create disparities.”
Rodriguez-Diaz is a community health scien-
tist by both training and passion, he says. “I serve 
as an adviser to the community. I’m a scientist, I 
conduct research, but I am not the kind of scien-
tist who tells the community what they need and 
what research we have to do,” says Rodriguez-
Diaz. “I like to work with the community in [such] 
a way that we come up together with the kind of 
research we need.”
Online Enlightenment
he GW Cancer Center offers evidence-based training and educational oppor-
tunities for health care professionals, patients, researchers, policymakers, and 
advocates, as well as others interested in cancer-related topics. The center’s 
online academy offers eight self-paced, no-cost courses on relevant topics for 
health care professionals, comprehensive cancer control programs, and others.
Among the online offerings is Addressing the Need for LGBTQI-Affirming Cancer Care: 
A Focus on Sexual and Gender Minority Prostate Cancer Survivors. The course helps so-
cial workers and other health care professionals support sexual and gender minority can-
cer patients. 
For more information about this and other GW Cancer Center training opportunities, 
visit gwccacademy.org.
For the past five years, Rodriguez-Diaz, who 
calls Puerto Rico home, has focused primar-
ily on sexual minorities — gay, lesbian, bisexual, 
transgender, and queer populations, as well as 
on Latin communities. Although his work is not 
always cancer-specific, he’s connected with Pratt-
Chapman during the time he’s been at GW to 
learn more about the LGBTQI community in D.C. 
Since his arrival, Rodriguez-Diaz has become a 
regular at CAB meetings, and he is working with 
other colleagues at Milken Institute SPH and DC 
Health on an HIV behavioral study with transgen-
der women. 
Rodriguez-Diaz adds that comprehensive under-
standing of the population rather than the disease 
itself “is key to solving the health disparities we see.”
Education and knowledge also must extend 
to students. Pratt-Chapman says she’s working 
with other important LGBTQI leaders at SMHS, in-
cluding Amy Caggiula, MD, assistant professor of 
emergency medicine, and Charles Samenow, MD, 
MPH, associate professor of psychiatry and behav-
ioral sciences, on ideas for mandatory and elec-
tive sessions to help medical students think about 
implicit bias and modeling affirming behaviors. 
“Understanding the needs of marginalized 
communities and meeting them where they are: 
these are things all health professionals, includ-
ing medical students, need to think about and be 
taught,” she says. 
T
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the george Washington university (gW) 
Cancer Center is continuing its work with the 
Centers for Disease Control and Prevention 
(CDC) by providing technical assistance for Na-
tional Comprehensive Cancer Control Program 
(NCCCP) grantees through a cooperative agree-
ment in excess of $4 million awarded to Mandi L. 
Pratt-Chapman, PhD, associate center director 
for patient-centered initiatives and health equity 
at the GW Cancer Center.
The new five-year award is a competitive re-
newal of the successful $2.1 million award from 
2013 to 2018. The cooperative agreement ex-
pands technical assistance efforts by leverag-
ing the existing infrastructure, capacity, and 
relationships of the talent at the GW Cancer 
Center’s Institute for Patient-Centered Initia-
tives and Health Equity to provide support to 
the grantees. 
NCCCP grantees create stakeholder-driven 
plans aimed at reducing the burden of cancer 
through evidence-based cancer control inter-
ventions adapted to local settings, this includes 
efforts to advance access to screening, treat-
ment, and cancer survivorship care and to re-
duce health inequities.
“CDC’s renewal of our work demonstrates the 
high value placed on our tailored, multilevel strat-
egies to advance cancer control and reduce health 
inequities across the nation,” says Pratt-Chapman. 
“We look forward to another strong half decade 
with this exciting and rewarding project.”
“CDC’s renewal of our work demonstrates the 
high value placed on our tailored, multilevel 
strategies to advance cancer control and 
reduce health inequities across the nation.”
MANDI L. PRATT-CHAPMAN, PhD
Pratt-Chapman Receives 
$4.125 Million to Continue 
Technical Assistance to 
Cancer Control Programs 
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hand smoke exposure 
among public housing 
residents. She has also 
partnered with Abroms 
— who is the found-
ing director of the GW 
mHealth Collaborative 
and a member of the 
GW Cancer Center — 
for the pilot, which is 
funded by the Milken 
Institute SPH Research 
Innovation Award. 
“Many of the resi-
dents in public hous-
ing have been smoking 
cigarettes for decades,” 
Bernat explains. “De-
spite this, many are interested in quitting.”
In 2008, Abroms developed Text2Quit, a text 
messaging smoking cessation program, which is 
now offered through the American Cancer So-
ciety/Optum Quit For Life program. The team 
plans to test a version of the program adapted to 
the context of D.C. public housing, which sends 
text messages motivating people to quit smoking 
— an intervention tactic that has become increas-
ingly common in behavioral change efforts such 
as smoking cessation. In addition to Text2Quit, 
residents will have access to Text4Coach, a text 
messaging program that links smokers to proac-
tive quitline counseling.
smoking is the leaDing Preventable cause 
of death in the United States. Despite reports 
from the Centers for Disease Control and Preven-
tion of a 20% decline in smoking between 2005 
and 2016, smoking rates among public housing 
residents remain more than twice as high as the 
national average. Cancer-related diseases, says 
Lorien Abroms, ScD, follow that same pattern. 
Abroms, a professor of prevention and commu-
nity health at Milken Institute School of Public 
Health (Milken Institute SPH) at the George Wash-
ington University (GW), created a pilot program 
for Washington, D.C., public housing residents 
who were interested in quitting smoking. She ex-
plains, “addressing the disparities is really impor-
tant for reducing cancer.”
In August 2018, the U.S. Department of Hous-
ing and Urban Development (HUD) issued a na-
tional ban on smoking in all public housing facili-
ties. When HUD passed the rule, many facilities 
were left without the resources to help their resi-
dents make the adjustment. 
The reasons for the ban on smoking are three-
fold, says Debra Bernat, PhD, associate professor 
of epidemiology and biostatistics at the Milken 
Institute SPH.
The first goal is to improve the health of resi-
dents, the second is to reduce fires, and the third 
is to reduce maintenance costs. Bernat is cur-
rently leading a study, funded by a grant from the 
National Institutes of Health, to understand how 
the rule affects smoking behavior and second-
HELPING HOUSING 
RESIDENTS QUIT
Lorien Abroms, ScD, created 
a pilot program for Wash-
ington, D.C., public housing 
residents who were inter-
ested in quitting smoking. 
Providing Resources for Smoking Cessation
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AT THE GW BREAST CARE CENTER, 
FUNDRAISERS AND DONATIONS UPLIFT PATIENT CARE
The Art of Giving
COMPLEMENTING 
PATIENT CARE
Christine Teal, MD, direc-
tor of the GW Breast Care 
Center and the chief of 
breast surgery, looks for 
new ways to comple-
ment patient care. Photo 
by Susan Gendron.
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centuries-old medicine uses hair-thin needles to 
stimulate points along the nervous system. 
Another specialty available during the clinic 
is reiki, a healing technique in which a therapist 
channels energy into the patient through touch 
to activate the natural healing processes of the 
patient’s body and restore well-being. 
“These offerings allow us to make the GW 
Breast Care Center a little more unique in what 
we can provide for patients,” says Teal. “And it’s 
a special bonus because insurance won’t cover 
these complementary therapies.”
In addition, the center uses the fund to have a 
physical therapist visit the clinic two afternoons a 
month. “Some of our patients, such as those who 
have had bilateral mastectomies with reconstruc-
tion, need stretching or more work, and through 
this they can be seen more than once a month 
when they are also seeing their surgeon,” Teal says. 
The fund isn’t supported just by the annual fund-
raiser, but also by current and former patients who 
want to give back. Teal says letters are sent out to 
patients who have experienced the complemen-
tary clinic to see if they would be willing to support 
it. “We often have a very nice response,” Teal notes. 
Teal also has held fundraising campaigns her-
self, including one two years ago in honor of her 
mother, who had breast surgery done at GW. 
“When the patients and community see how near 
and dear it is to me to provide these programs, 
they see the importance of it,” she says.
She adds that seeing current patients and for-
mer patients give back, including those who have 
been giving for many years, is heartening. “It 
doesn’t have to be a big donation. Just that they 
are willing to give is meaningful,” she says.
diagnosis of breast cancer is 
a scary moment in any per-
son’s life, and going through 
treatment can be difficult on 
both the mind and the body, 
but at the George Washing-
ton University (GW) Cancer 
Center, the journey can be made a little easier 
thanks to support from current and former pa-
tients and community members.
Through a patient and community member-
supported patient assistance fund, the GW 
Breast Care Center is able to offer financial 
assistance and a monthly complementary care 
clinic for patients. The fund was started in 2007 
by GW patient LuAnn Dean. 
Some of the money that goes into the fund is 
collected during a fundraiser often held in the 
fall. The fundraiser has looked different over the 
years; such as silent auctions or golf tournaments. 
“The fundraiser and patient assistance fund 
have really enabled us to help our patients both 
financially and through a holistic care program,” 
says Christine Teal, MD, director of the GW Breast 
Care Center and the chief of breast surgery. 
Financial support can include helping 
patients pay their rent or providing them with 
transportation options, she says.
Then there’s the complementary clinic, which 
Teal says the patients love. It’s offered once a 
month and is supported by providers from the 
GW Center for Integrative Medicine. During the 
clinics, patients have the opportunity to sample a 
variety of complementary medicine options. They 
can meet with a naturopath, who can discuss with 
them natural approaches to cancer treatment, as 
well as provide advice on what supplements may 
help ease pain and offer nutritional counseling. 
Patients may also receive acupuncture therapy 
to help relieve nausea from chemotherapy; the 
BY KATHERINE DVORAK
WITH PATIENT AND 
COMMUNITY SUPPORT
Christine Teal, MD, says 
a patient and commu-
nity member-supported 
patient assistance fund 
makes the GW Breast 
Care Center unique in 
what it can provide for 
patients. The fund was 
started in 2007 by GW 
patient LuAnn Dean.A
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THE GW MEDICAL  
FACULTY ASSOCIATES (MFA)
2150 Pennsylvania Ave., NW
Washington, D.C. 20037
ALL CANCERS
Open to all cancer patients currently in 
treatment. Registration required.
Second and fourth Wednesday of each 
month, 12:30–1:30 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker 
202-677-6229
CAREGIVER SUPPORT GROUP
Open to caregivers of those diagnosed 
with cancer to share common concerns, 
give and receive advice, and learn 
coping skills. Registration required.
Third Tuesday of each month
12:30–1:30 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582
GENTLE YOGA
This group introduces patients 
and caregivers to the physical and 
emotional benefits of yoga.
Tuesdays, 4–5 p.m.
GW Marvin Center,  
fifth floor activities room
800 21st St., NW
Facilitator: Yael Flusberg
dgarcia@mfa.gwu.edu
202-741-2582
The George Washington University Cancer Center, with support provided by the Dr. Cyrus and Myrtle 
Katzen Cancer Research Center, supports a wide variety of holistic and wellness services for cancer 
patients and their families. These groups are free of charge and open to the community.
SUPPORT GROUPS
HEAD AND NECK CANCER GROUP
For head and neck cancer patients 
and survivors, and their caregivers. 
Registration required.
First Tuesday of each month
12:30–1:30 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582
METASTATIC BREAST  
CANCER SUPPORT GROUP 
This group is open to metastatic breast 
cancer patients. Registration required.
Fourth Tuesday of each month
Noon–1 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582
MULTIPLE MYELOMA GROUP
This group is open to multiple 
myeloma patients and survivors, and 
their caregivers. Registration required.
Third Tuesday of each month
5:30–6:30 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582
NUTRITION CLUB
This group is open to patients and 
survivors, and their caregivers. 
Registration required.
First Monday of each month
Noon–1 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Jennifer Leon
jleon@mfa.gwu.edu
202-741-6489
PROSTATE CANCER GROUP
The prostate cancer education group 
is open to patients and survivors, and 
their caregivers. Registration required.
Second Tuesday of each month
6–7 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582
SURVIVORSHIP SERIES
An educational series featuring a 
different speaker each month.
Second Thursday of each month
11:45 a.m.–12:45 p.m.
GW Cancer Center Boardroom
MFA, first floor, 1-402
Facilitator: Oncology Social Worker
202-741-2582
YOUNG ADULT GROUP
Young adults (19–39 years of age) who 
are currently in treatment or are cancer 
survivors.
Third Sunday of each month
5–6:30 p.m.
Smith Center for Healing and the Arts
1632 U St., NW
Facilitator: Jennifer Bires, LiCSW, OSW
202-483-8600
Parking is validated for all groups 
at the GW Cancer Center. For 
more information about upcoming 
support groups and events, visit 
cancercenter.gwu.edu/for-patients/
patientcaregiver-support.
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Joel hinzman is a busy dad, husband, and lob-
byist who never expected to be diagnosed with 
tonsil cancer at age 46. The first sign of a problem 
was swelling on the left side of his neck that got 
worse and more painful, despite taking antibiot-
ics. In seeking cancer treatment, one option that is 
part of a clinical study at the George Washington 
University (GW) Cancer Center stood out, based 
on Hinzman’s research. “It looked like it had great 
long-term outcomes and the best chance for min-
imum side effects over the long term,” he says. 
Maintaining his quality of life was important to 
him, and he wanted to enjoy eating and his sense 
of taste when his treatment was done.
Game-changing care
The type of cancer Hinzman had was associated 
with the human papillomavirus (HPV). Traditional-
ly, treatment in these cases has involved chemo-
therapy and radiation, says Director of Head and 
Neck Oncologic and Microvascular Reconstruc-
tive Surgery Arjun Joshi, MD, FACS, FRCS(C). 
However, patients in the clinical study, explains 
Joshi, who also serves as professor of surgery at 
TO TREAT HEAD AND NECK CANCERS, GW HOSPITAL 
OFFERS THE MEDROBOTICS FLEX® ROBOTIC SYSTEM.
This innovative technology is designed to navigate the body’s twists and 
turns and can provide a compelling resource for treating other conditions 
as well. Minimally invasive robotic surgery can reduce pain and trauma 
to the body, leading to a shorter hospital stay and a quicker recovery.
GW School of Medi-
cine and Health Sci-
ences (SMHS), and as 
a member of the GW 
Cancer Center, re-
ceive chemotherapy 
and then robotic sur-
gery avoiding radia-
tion and its potential 
lifelong side effects, such as dry mouth, changes 
in taste, dental disease, and others.
Within 48 hours of his first dose of chemother-
apy, Hinzman noticed that the tumor on his neck 
was significantly smaller. By the end of the third 
treatment, the cancer was hard to find. He then 
underwent surgery to remove what tumor re-
mained at the tonsil and in the lymph nodes in his 
neck. Pathology showed that the tumor at both 
sites had disappeared. He remains cancer-free 
more than two years after surgery. Also, he has no 
problems with taste or swallowing, and is grateful 
to have his normal oral functioning intact. “I had 
great care at GW Hospital and as an outpatient,” 
he says of his treatment led by Joshi and medical 
oncologist Robert Siegel, MD, associate center 
director for professional outreach and networks 
at the GW Cancer Center.
Hinzman adds, “I appreciated the fact that I 
was at a teaching hospital, with great residents 
coming in and checking on me regularly.” 
Innovative Cancer 
Treatment Made Care 
Easier to Swallow
DID YOU KNOW it is estimated that about 3,400 
new cases of HPV-associated oropharyngeal cancers 
are diagnosed in women and about 14,800 are 
diagnosed in men each year in the United States.?
BEST LONG-TERM OUTCOME
Diagnosed with tonsil cancer 
at age 46, Joel Hinzman took 
part in a clinical study at the 
George Washington Universi-
ty Cancer Center because that 
treatment offered the best 
outcome over the long term.
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